PMID- 28070993
OWN - NLM
STAT- MEDLINE
DCOM- 20170711
LR  - 20220408
IS  - 1862-1783 (Electronic)
IS  - 1673-1581 (Print)
IS  - 1673-1581 (Linking)
VI  - 18
IP  - 1
DP  - 2017 Jan.
TI  - Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in 
      clinical practice.
PG  - 15-26
LID - 10.1631/jzus.B1600303 [doi]
AB  - Breast cancer is one of the malignant tumors with the highest morbidity and 
      mortality. It is helpful to reduce the rate of tumor recurrence and metastasis by 
      treating breast cancer with adjuvant chemotherapy, so as to increase the cure 
      rate or survival of patients. In recent years, liposomes have been regarded as a 
      kind of new carrier for targeted drugs. Being effective for enhancing drug 
      efficacy and reducing side effects, they have been widely used for developing 
      anticancer drugs. As a kind of anthracycline with high anticancer activity, 
      doxorubicin can treat or alleviate a variety of malignant tumors effectively when 
      it is used on its own or in combination with other anticancer drugs. Although 
      liposomal doxorubicin has been extensively used in the adjuvant chemotherapy of 
      breast cancer, its exact therapeutic efficacy and side effects have not been 
      definitely proven. Various clinical studies have adopted different combined 
      regimes, dosages, and staging, so their findings differ to certain extent. This 
      paper reviews the clinical application of liposomal doxorubicin in the adjuvant 
      chemotherapy of breast cancer and illustrates therapeutic effects and side 
      effects of pegylated liposomal doxorubicin (PLD) and non-PLD (NPLD) in clinical 
      research, in order to discuss the strategies for applying these drugs in such 
      adjuvant chemotherapy, looking forward to providing references for related 
      research and clinical treatment in terms of dosage, staging, combined regimes, 
      and analysis methods and so on.
FAU - Zhao, Ming
AU  - Zhao M
AD  - College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
FAU - Ding, Xian-Feng
AU  - Ding XF
AD  - College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
FAU - Shen, Jian-Yu
AU  - Shen JY
AD  - College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou 310018, China.
FAU - Zhang, Xi-Ping
AU  - Zhang XP
AD  - Department of Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
FAU - Ding, Xiao-Wen
AU  - Ding XW
AD  - Department of Tumor Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, China.
FAU - Xu, Bin
AU  - Xu B
AD  - Institute of Occupational Diseases, Zhejiang Academy of Medical Sciences, 
      Hangzhou 310013, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - J Zhejiang Univ Sci B
JT  - Journal of Zhejiang University. Science. B
JID - 101236535
RN  - 0 (Anthracyclines)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Lipid Bilayers)
RN  - 0 (liposomal doxorubicin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Animals
MH  - Anthracyclines/therapeutic use
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - Antineoplastic Agents/therapeutic use
MH  - Apoptosis
MH  - Breast Neoplasms/*drug therapy
MH  - Chemotherapy, Adjuvant/*methods
MH  - Doxorubicin/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Lipid Bilayers
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Polyethylene Glycols/chemistry/therapeutic use
MH  - Prognosis
MH  - Receptor, ErbB-2/metabolism
PMC - PMC5260474
OTO - NOTNLM
OT  - Liposomal doxorubicin; Breast cancer; Adjuvant chemotherapy; Therapeutic effect; 
      Toxic and side effects
COIS- Compliance with ethics guidelines: Ming ZHAO, Xian-feng DING, Jian-yu SHEN, 
      Xi-ping ZHANG, Xiao-wen DING, and Bin XU declare that they have no conflict of 
      interest. The article does not contain any studies with human or animal subjects 
      performed by any of the authors.
EDAT- 2017/01/11 06:00
MHDA- 2017/07/14 06:00
PMCR- 2017/01/01
CRDT- 2017/01/11 06:00
PHST- 2017/01/11 06:00 [entrez]
PHST- 2017/01/11 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.1631/jzus.B1600303 [doi]
PST - ppublish
SO  - J Zhejiang Univ Sci B. 2017 Jan.;18(1):15-26. doi: 10.1631/jzus.B1600303.